Beijing: China conditionally approved the registration application of a self-developed recombinant protein subunit vaccine against Covid-19, the National Medical Products Administration said Wednesday.
The vaccine, developed by Anhui Zhifei Longcom Biopharmaceutical Co, Ltd., was allowed to enter the market on a conditional basis, said the administration, Xinhua news agency reported.
It marked the first approved Covid recombinant protein subunit vaccine in China.
